The University of Southampton
University of Southampton Institutional Repository

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial
Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial

Background: infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. 

Methods: in this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. 

Findings: we recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention.

Interpretation: enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. 

Funding: UK National Institute for Health Research Health Technology Assessment programme (10/57/49).

0140-6736
423-433
Griffiths, James
dca66bc8-f1c8-4bed-b81b-bfba94c27443
Jenkins, Paula
d5599aff-ad0f-439c-b2f8-de4e9dab14ba
Vargova, Monika
05b9767c-60d2-4f67-b7fa-469b69e538d6
Bowler, Ursula
49570c44-66b8-4121-a220-3de7e6cf1a0d
Juszczak, Edmund
9267758e-8ab8-44c7-ab14-48ef82fa6b6e
King, Andrew
a0afaa80-e458-45a3-a3ca-6619c784b8da
Linsell, Louise
bf220517-49cd-4fbb-8666-19d2a1de1257
Murray, David
3d2edcb9-2d12-4849-854a-937cd7938dc6
Partlett, Christopher
ff1ea90b-5254-4a96-809a-14d05b13a0d7
Patel, Mehali
c589a05c-d5b3-409e-80c1-70c1b236fdeb
Berrington, Janet
7abdd601-9ade-4b12-a5ef-22fac14ae86f
Dorling, Jon
e55dcb9a-a798-41a1-8753-9e9ff8aab630
Embleton, Nicholas D.
5c621f1e-cee5-4efa-ac43-8a195410c11c
Heath, Paul T.
751321bd-5245-4f79-b57a-6d3b6de61b32
Oddie, Sam
6a5511a3-e72e-4274-a120-aecde541f46b
McGuire, William
aed9d25e-dc0a-4813-96e1-156c268e005c
Ainsworth, Sean
62a1a085-f5c4-4c46-91bd-5279458d26f8
Boyle, Elaine
0a18aac0-3ba2-4463-a07c-f5957ed4ceb7
Clarke, Paul
962f7c73-1c1e-4719-bfc4-9e5e8ac1fe9c
Craig, Stanley
2165cb30-a469-47b8-99dd-c116857b5c7a
Johnson, Kathryn
07bdaaf5-20d7-4a42-b565-8f840490bb59
Mactier, Helen
eb1043b6-9fa4-491e-861c-2491db247225
Scorrer, Tim
f0c5dbf1-c32c-46df-90f6-c1bc6ac17e1b
Ledwidge, Mary
144f4583-b3bd-4731-92a3-06503a05db61
Story, Imogen
fac3a1e4-836b-47b0-8d5f-5e87829e3b78
Holder, Gemma
cf2b539a-4998-47ea-b768-83a1d9193334
Ohadike, Pamela
8058c9ff-aeb5-47b3-ae2d-bfa7a5bd95ea
Ellis, Sarah
d640e74f-aa8d-4d3a-83f7-b8078607f0fb
Vaikute, Rima
3811f0b2-54af-45ee-81e9-a3e68bbc8772
Gowda, Girish
9680a926-7dbf-40aa-88d3-98c68efbdd4d
Yates, Helen
fce8805c-bf9f-4c47-ae4e-f3e67425588f
Garg, Shalabh
ade82048-d67e-4d50-95b5-ca401815ee32
Pilling, Elizabeth
cbeddce7-ab66-4f14-a5fc-77f1c3969a99
Roehr, Charles
9842b358-0375-4d15-857b-9cf78f02c941
Batra, Dushyant
80313b63-1f03-4572-a107-b129b5b652ca
Gibson, David
cc42797b-e604-420e-8ef5-47603e56cf70
Johnson, Mark
ce07b5dd-b12b-47df-a5df-cd3b9447c9ed
Kumar, Yadlapalli
853b6726-ebb1-4873-a83d-120d318e86d9
Bartle, David
7de59862-693f-44de-a39c-38e32de0896e
Peters, Colin
a12443ca-c5dd-41b1-98ff-0ce0d5c458c6
Quine, David
d300e1aa-1ecb-426e-b35c-9a527c431c97
Gupta, Richa
d72e67a3-c40f-4e55-aa25-713bd5affb1e
Matthes, Jean
f42cdedd-ae08-4671-9729-b6d389462d77
Kennea, Nigel
954ec72a-dcdc-4c9b-a407-28dbadc8e8fe
Reynolds, Peter
809f032a-bf9c-42df-a101-85197fd1ce12
Geethanath, Ruppa
0d3143c0-88b3-4357-ab47-3b7e980a84d1
Janakiraman, Sundaram
1cfaa150-83c9-49b1-83d6-52d59d4eb2a3
Vasu, Vimal
9b2fce3f-aea9-42bc-a2c5-246ff387422f
Manjunatha, C.M.
c0feacd7-acf6-41a8-8f9c-a9fd938f82ee
The ELFIN trial investigators group
Griffiths, James
dca66bc8-f1c8-4bed-b81b-bfba94c27443
Jenkins, Paula
d5599aff-ad0f-439c-b2f8-de4e9dab14ba
Vargova, Monika
05b9767c-60d2-4f67-b7fa-469b69e538d6
Bowler, Ursula
49570c44-66b8-4121-a220-3de7e6cf1a0d
Juszczak, Edmund
9267758e-8ab8-44c7-ab14-48ef82fa6b6e
King, Andrew
a0afaa80-e458-45a3-a3ca-6619c784b8da
Linsell, Louise
bf220517-49cd-4fbb-8666-19d2a1de1257
Murray, David
3d2edcb9-2d12-4849-854a-937cd7938dc6
Partlett, Christopher
ff1ea90b-5254-4a96-809a-14d05b13a0d7
Patel, Mehali
c589a05c-d5b3-409e-80c1-70c1b236fdeb
Berrington, Janet
7abdd601-9ade-4b12-a5ef-22fac14ae86f
Dorling, Jon
e55dcb9a-a798-41a1-8753-9e9ff8aab630
Embleton, Nicholas D.
5c621f1e-cee5-4efa-ac43-8a195410c11c
Heath, Paul T.
751321bd-5245-4f79-b57a-6d3b6de61b32
Oddie, Sam
6a5511a3-e72e-4274-a120-aecde541f46b
McGuire, William
aed9d25e-dc0a-4813-96e1-156c268e005c
Ainsworth, Sean
62a1a085-f5c4-4c46-91bd-5279458d26f8
Boyle, Elaine
0a18aac0-3ba2-4463-a07c-f5957ed4ceb7
Clarke, Paul
962f7c73-1c1e-4719-bfc4-9e5e8ac1fe9c
Craig, Stanley
2165cb30-a469-47b8-99dd-c116857b5c7a
Johnson, Kathryn
07bdaaf5-20d7-4a42-b565-8f840490bb59
Mactier, Helen
eb1043b6-9fa4-491e-861c-2491db247225
Scorrer, Tim
f0c5dbf1-c32c-46df-90f6-c1bc6ac17e1b
Ledwidge, Mary
144f4583-b3bd-4731-92a3-06503a05db61
Story, Imogen
fac3a1e4-836b-47b0-8d5f-5e87829e3b78
Holder, Gemma
cf2b539a-4998-47ea-b768-83a1d9193334
Ohadike, Pamela
8058c9ff-aeb5-47b3-ae2d-bfa7a5bd95ea
Ellis, Sarah
d640e74f-aa8d-4d3a-83f7-b8078607f0fb
Vaikute, Rima
3811f0b2-54af-45ee-81e9-a3e68bbc8772
Gowda, Girish
9680a926-7dbf-40aa-88d3-98c68efbdd4d
Yates, Helen
fce8805c-bf9f-4c47-ae4e-f3e67425588f
Garg, Shalabh
ade82048-d67e-4d50-95b5-ca401815ee32
Pilling, Elizabeth
cbeddce7-ab66-4f14-a5fc-77f1c3969a99
Roehr, Charles
9842b358-0375-4d15-857b-9cf78f02c941
Batra, Dushyant
80313b63-1f03-4572-a107-b129b5b652ca
Gibson, David
cc42797b-e604-420e-8ef5-47603e56cf70
Johnson, Mark
ce07b5dd-b12b-47df-a5df-cd3b9447c9ed
Kumar, Yadlapalli
853b6726-ebb1-4873-a83d-120d318e86d9
Bartle, David
7de59862-693f-44de-a39c-38e32de0896e
Peters, Colin
a12443ca-c5dd-41b1-98ff-0ce0d5c458c6
Quine, David
d300e1aa-1ecb-426e-b35c-9a527c431c97
Gupta, Richa
d72e67a3-c40f-4e55-aa25-713bd5affb1e
Matthes, Jean
f42cdedd-ae08-4671-9729-b6d389462d77
Kennea, Nigel
954ec72a-dcdc-4c9b-a407-28dbadc8e8fe
Reynolds, Peter
809f032a-bf9c-42df-a101-85197fd1ce12
Geethanath, Ruppa
0d3143c0-88b3-4357-ab47-3b7e980a84d1
Janakiraman, Sundaram
1cfaa150-83c9-49b1-83d6-52d59d4eb2a3
Vasu, Vimal
9b2fce3f-aea9-42bc-a2c5-246ff387422f
Manjunatha, C.M.
c0feacd7-acf6-41a8-8f9c-a9fd938f82ee

Griffiths, James, Jenkins, Paula, Vargova, Monika, Bowler, Ursula, Juszczak, Edmund, King, Andrew, Linsell, Louise, Murray, David, Partlett, Christopher, Patel, Mehali, Berrington, Janet, Dorling, Jon, Embleton, Nicholas D., Heath, Paul T., Oddie, Sam, McGuire, William, Ainsworth, Sean, Boyle, Elaine, Clarke, Paul, Craig, Stanley, Johnson, Kathryn, Mactier, Helen, Scorrer, Tim, Ledwidge, Mary, Story, Imogen, Holder, Gemma, Ohadike, Pamela, Ellis, Sarah, Vaikute, Rima, Gowda, Girish, Yates, Helen, Garg, Shalabh, Pilling, Elizabeth, Roehr, Charles, Batra, Dushyant, Gibson, David, Johnson, Mark, Kumar, Yadlapalli, Bartle, David, Peters, Colin, Quine, David, Gupta, Richa, Matthes, Jean, Kennea, Nigel, Reynolds, Peter, Geethanath, Ruppa, Janakiraman, Sundaram, Vasu, Vimal and Manjunatha, C.M. , The ELFIN trial investigators group (2019) Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. The Lancet, 393 (10170), 423-433. (doi:10.1016/S0140-6736(18)32221-9).

Record type: Article

Abstract

Background: infections acquired in hospital are an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein processed from cow's milk, prevents infections and associated complications. The aim of this large randomised controlled trial was to collect data to enhance the validity and applicability of the evidence from previous trials to inform practice. 

Methods: in this randomised placebo-controlled trial, we recruited very preterm infants born before 32 weeks' gestation in 37 UK hospitals and younger than 72 h at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Eligible infants were randomly assigned (1:1) to receive either enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day; lactoferrin group) or sucrose (same dose; control group) once daily until 34 weeks' postmenstrual age. Web-based randomisation minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers, and outcome assessors were unaware of group assignment. The primary outcome was microbiologically confirmed or clinically suspected late-onset infection (occurring >72 h after birth), which was assessed in all participants for whom primary outcome data was available by calculating the relative risk ratio with 95% CI between the two groups. The trial is registered with the International Standard Randomised Controlled Trial Number 88261002. 

Findings: we recruited 2203 participants between May 7, 2014, and Sept 28, 2017, of whom 1099 were assigned to the lactoferrin group and 1104 to the control group. Four infants had consent withdrawn or unconfirmed, leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants (1093 [99·5%] of 1098 in the lactoferrin group and 1089 [99·0] of 1101 in the control group) were available for inclusion in the modified intention-to-treat analyses. 316 (29%) of 1093 infants in the intervention group acquired a late-onset infection versus 334 (31%) of 1089 in the control group. The risk ratio adjusted for minimisation factors was 0·95 (95% CI 0·86–1·04; p=0·233). During the trial there were 16 serious adverse events for infants in the lactoferrin group and 10 for infants in the control group. Two events in the lactoferrin group (one case of blood in stool and one death after intestinal perforation) were assessed as being possibly related to the trial intervention.

Interpretation: enteral supplementation with bovine lactoferrin does not reduce the risk of late-onset infection in very preterm infants. These data do not support its routine use to prevent late-onset infection and associated morbidity or mortality in very preterm infants. 

Funding: UK National Institute for Health Research Health Technology Assessment programme (10/57/49).

Text
1-s2.0-S0140673618322219-main - Version of Record
Download (362kB)

More information

e-pub ahead of print date: 8 January 2019
Published date: 31 January 2019
Additional Information: Funding Information: The ELFIN trial was funded by the National Institute for Health Research—Health Technology Assessment Programme (10/57/49). We thank all the parents of participating infants and all staff and carers in recruiting and continuing care sites. We thank the members of the independent Data Monitoring Committee and Trial Steering Committee; the Newcastle Specials Pharmacy team; Bliss ; Tatua Dairy Co-operative, New Zealand; and the administrative and support colleagues at the NPEU CTU.

Identifiers

Local EPrints ID: 478823
URI: http://eprints.soton.ac.uk/id/eprint/478823
ISSN: 0140-6736
PURE UUID: 71fdc501-9d3b-4903-bc74-e612373a05ea
ORCID for Jon Dorling: ORCID iD orcid.org/0000-0002-1691-3221
ORCID for Mark Johnson: ORCID iD orcid.org/0000-0003-1829-9912

Catalogue record

Date deposited: 11 Jul 2023 16:53
Last modified: 18 Sep 2024 02:10

Export record

Altmetrics

Contributors

Author: James Griffiths
Author: Paula Jenkins
Author: Monika Vargova
Author: Ursula Bowler
Author: Edmund Juszczak
Author: Andrew King
Author: Louise Linsell
Author: David Murray
Author: Christopher Partlett
Author: Mehali Patel
Author: Janet Berrington
Author: Jon Dorling ORCID iD
Author: Nicholas D. Embleton
Author: Paul T. Heath
Author: Sam Oddie
Author: William McGuire
Author: Sean Ainsworth
Author: Elaine Boyle
Author: Paul Clarke
Author: Stanley Craig
Author: Kathryn Johnson
Author: Helen Mactier
Author: Tim Scorrer
Author: Mary Ledwidge
Author: Imogen Story
Author: Gemma Holder
Author: Pamela Ohadike
Author: Sarah Ellis
Author: Rima Vaikute
Author: Girish Gowda
Author: Helen Yates
Author: Shalabh Garg
Author: Elizabeth Pilling
Author: Charles Roehr
Author: Dushyant Batra
Author: David Gibson
Author: Mark Johnson ORCID iD
Author: Yadlapalli Kumar
Author: David Bartle
Author: Colin Peters
Author: David Quine
Author: Richa Gupta
Author: Jean Matthes
Author: Nigel Kennea
Author: Peter Reynolds
Author: Ruppa Geethanath
Author: Sundaram Janakiraman
Author: Vimal Vasu
Author: C.M. Manjunatha
Corporate Author: The ELFIN trial investigators group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×